Who Owns Kyverna Therapeutics Stock?
NASDAQ: KYTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 79.14%
- Held by insiders
- 7.68%
- Institutional holders
- 182
- Institutions 79.1%
- Insiders 7.7%
- Public and other 13.2%
Who owns Kyverna Therapeutics stock?
Institutional investors own about 79.1% of Kyverna Therapeutics's shares, spread across 182 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 7.68% of KYTX.
The largest institutional holders are GordonMD Global Investments LP (6.86%), Gilead Sciences Inc (6.67%) and AIGH Capital Management LLC (5.90%). Together, the top 10 institutions control 41.0% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their KYTX positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of KYTX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| GordonMD Global Investments LP | 4.24M | 6.86% | 0.0% |
| Gilead Sciences Inc | 4.13M | 6.67% | 0.0% |
| AIGH Capital Management LLC | 3.65M | 5.90% | +30.6% |
| Blackrock Inc. | 3.13M | 5.07% | +257.4% |
| Bain Capital Life Sciences Investors, LLC | 2.88M | 4.67% | -7.2% |
| Deerfield Management Company, L.P | 2.00M | 3.23% | 0.0% |
| Vanguard Capital Management LLC | 1.90M | 3.07% | +6.4% |
| State Street Corporation | 1.20M | 1.95% | +22.5% |
| Price (T.Rowe) Associates Inc | 1.19M | 1.92% | -23.7% |
| Geode Capital Management, LLC | 1.05M | 1.70% | +0.4% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of KYTX
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.40M | 2.27% |
| iShares Trust-iShares Russell 2000 ETF | 1.11M | 1.79% |
| T. Rowe Price Health Sciences Fund, Inc. | 856.80K | 1.39% |
| Fidelity Commonwealth Trust II-Fidelity Enhanced Small Cap Core ETF | 487.96K | 0.79% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 459.63K | 0.74% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 448.15K | 0.72% |
| iShares Trust-iShares Russell 2000 Value ETF | 353.70K | 0.57% |
| iShares Trust-iShares Biotechnology ETF | 294.01K | 0.48% |
| SPDR SERIES TRT-State Street SPDR S&P Kensho New Economies Composite E | 259.50K | 0.42% |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 240.59K | 0.39% |
Frequently asked questions
Who is the largest shareholder of Kyverna Therapeutics?
GordonMD Global Investments LP is the largest institutional shareholder of KYTX, owning 6.86% of shares outstanding (4.24M shares) as of its latest 13F filing.
What percentage of Kyverna Therapeutics is owned by institutions?
Institutions own about 79.1% of KYTX shares and 85.7% of the public float.
How much of Kyverna Therapeutics do insiders own?
Insiders, such as officers and directors, own about 7.68% of KYTX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.